159 related articles for article (PubMed ID: 37810968)
1. Case Report: A rare case of non-small cell lung cancer with STRN-ALK fusion in a patient in very poor condition treated with first-line ensartinib.
Song GQ; Li YZ; Kong W; Hu GQ
Front Oncol; 2023; 13():1235679. PubMed ID: 37810968
[TBL] [Abstract][Full Text] [Related]
2. STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report.
Zhang L; Xiao P; Meng F; Zhong D
Curr Oncol; 2022 Sep; 29(10):6749-6753. PubMed ID: 36290807
[TBL] [Abstract][Full Text] [Related]
3. Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion.
Li X; Zheng J; Li X; Chen Y; Liu K; Li F; Lu Z
Front Oncol; 2023; 13():1252221. PubMed ID: 37869075
[TBL] [Abstract][Full Text] [Related]
4.
Su C; Jiang Y; Jiang W; Wang H; Liu S; Shao Y; Zhao W; Ning R; Yu Q
Onco Targets Ther; 2020; 13():12515-12519. PubMed ID: 33311990
[TBL] [Abstract][Full Text] [Related]
5. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Efficacy of ensartinib treatment in pulmonary inflammatory myofibroblastic tumor with a rare
He W; Ji X; Song C; Song S; Liu L
Front Oncol; 2022; 12():934887. PubMed ID: 36003768
[TBL] [Abstract][Full Text] [Related]
7. A Rare
Yang Y; Qin SK; Zhu J; Wang R; Li YM; Xie ZY; Wu Q
Mayo Clin Proc Innov Qual Outcomes; 2017 Jul; 1(1):111-116. PubMed ID: 30225407
[TBL] [Abstract][Full Text] [Related]
8. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant target therapy with ensartinib in lung adenocarcinoma with EML4-ALK fusion variant: a case report and literature review.
Wu Y; Huang L; Li W; Chai Y
Anticancer Drugs; 2023 Jun; 34(5):699-706. PubMed ID: 36730477
[TBL] [Abstract][Full Text] [Related]
10. [Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation
Treated with Ensartinib: A Case Report and Literature Review].
Lv D; Xu C; Wang C; Sang Q
Zhongguo Fei Ai Za Zhi; 2023 Jan; 26(1):78-82. PubMed ID: 36792084
[TBL] [Abstract][Full Text] [Related]
11. Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.
Zeng Q; Gao H; Zhang L; Qin S; Gu Y; Chen Q
Anticancer Drugs; 2021 Sep; 32(8):890-893. PubMed ID: 34232939
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
Luo X; Zhou Z; Zeng X; Peng L; Liu Q
Front Public Health; 2022; 10():985834. PubMed ID: 36211665
[TBL] [Abstract][Full Text] [Related]
13. A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review.
Miyagawa C; Takaya H; Sakai K; Nishio K; Konishi M; Minamiguchi S; Shimada T; Matsumura N
Oncologist; 2021 May; 26(5):356-361. PubMed ID: 33555117
[TBL] [Abstract][Full Text] [Related]
14. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Horn L; Wang Z; Wu G; Poddubskaya E; Mok T; Reck M; Wakelee H; Chiappori AA; Lee DH; Breder V; Orlov S; Cicin I; Cheng Y; Liu Y; Fan Y; Whisenant JG; Zhou Y; Oertel V; Harrow K; Liang C; Mao L; Selvaggi G; Wu YL
JAMA Oncol; 2021 Nov; 7(11):1617-1625. PubMed ID: 34473194
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Resistance Mutations Against Upcoming Anaplastic Lymphoma Kinase Inhibitors.
Doi Y; Tagaya H; Noge A; Semba K
Target Oncol; 2022 Nov; 17(6):695-707. PubMed ID: 36201110
[TBL] [Abstract][Full Text] [Related]
16. Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations.
Yang X; Zhong J; Yu Z; Zhuo M; Zhang M; Chen R; Xia X; Zhao J
BMC Cancer; 2021 Oct; 21(1):1107. PubMed ID: 34654390
[TBL] [Abstract][Full Text] [Related]
17. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer.
Xiang Y; Zhang S; Fang X; Jiang Y; Fang T; Liu J; Lu K
Curr Oncol; 2022 Oct; 29(10):7816-7831. PubMed ID: 36290895
[TBL] [Abstract][Full Text] [Related]
19. Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial.
Ma Y; Pan H; Liu Y; Zhang Y; Hong S; Huang J; Weng S; Yang Y; Fang W; Huang Y; Xiao S; Wang T; Ding L; Cui L; Zhang L; Zhao H
J Thorac Dis; 2022 Dec; 14(12):4751-4762. PubMed ID: 36647478
[TBL] [Abstract][Full Text] [Related]
20. Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer.
Fukui T; Tachihara M; Nagano T; Kobayashi K
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
